Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Multiple Myeloma 10Neoplasms 8Lymphoma 7Carcinoma, Non-Small-Cell Lung 7Leukemia, Myeloid, Acute 6Prostatic Neoplasms 5Lymphoma, Non-Hodgkin 5Hodgkin Disease 5Neoplasms, Plasma Cell 4Advanced Solid Tumors 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Melanoma 3Lung Neoplasms 3Leukemia 3Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Solid Tumors 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hematologic Neoplasms 2Head and Neck Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × Panobinostat × Clear all
NCT00550199 2013-08-19

LBH589 and Gemcitabine in the Treatment of Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Terminated
17 enrolled
Other solid neoplasm

Solid Tumors

NCT00556088 2010-12-30

LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
40 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡